SCHEMBL30292007

SCHEMBL30292007

O=Cc1ccc([N+](=O)[O-])cc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.53
PDE7A Q13946 1/20 0.48
ALDH1A1 P00352 7/20 0.47
POLB P06746 1/20 0.46
PTPN1 P18031 1/20 0.43
AR P10275 3/20 0.43
TXNRD1 Q16881 1/20 0.42
TXNRD3 Q86VQ6 1/20 0.42
TXNRD2 Q9NNW7 1/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.42
HTT P42858 2/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
HIF1A Q16665 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460265 1.00 ERN1 (0.53) ERN1PDE7AALDH1A1POLBPTPN1
SCHEMBL28103378 0.85 PDE7A (0.47) ERN1PDE7AALDH1A1POLBAR
SCHEMBL1999857 0.80 PDE7A (0.54) PDE7AALDH1A1POLBARMAPT
SCHEMBL3207733 0.78 AR (0.53) PDE7AALDH1A1POLBARMAPT
SCHEMBL3353163 0.78 ERN1 (0.44) ERN1PDE7AALDH1A1POLBPTPN1
SCHEMBL2652355 0.77 ERN1 (0.69) ERN1ALDH1A1PTPN1TXNRD1TXNRD3
SCHEMBL2462136 0.77 GLO1 (0.52) PDE7AALDH1A1POLBMAPTMAPK1
SCHEMBL85544 0.77 ALDH1A1 (0.58) PDE7AALDH1A1POLBARMAPT
SCHEMBL31138869 0.77 ALDH1A1 (0.53) PDE7AALDH1A1POLBARTXNRD1
SCHEMBL3965308 0.77 PDE7A (0.51) PDE7AALDH1A1POLBARMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617801-B2 Tetrahydrothieno pyridine derivatives as DDRS inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-05 US disclosed
EP-4313994-B1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-03-05 EP disclosed
CN-113227086-B N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal disorders 内生疗法公司 2024-07-26 CN disclosed
US-20240199635-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-06-20 US disclosed
EP-4167999-A1 NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM Endogena Therapeutics, Inc. (US) 2023-04-26 EP disclosed
CN-115996917-A 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors 艾捷斯治疗公司 2023-04-21 CN disclosed
CN-115916192-A Novel compounds and their use as therapeutically active substances for the treatment and/or prophylaxis of diseases in which the retinal pigment epithelium is involved 内生疗法公司 2023-04-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617801-B2 Tetrahydrothieno pyridine derivatives as DDRS inhibitors DDR1, DDR2, DDRGK1 ERN1 1465/4885PDE7A 1010/4885ALDH1A1 3606/4885
US-20240199635-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 ERN1 1537/4885PDE7A 1353/4885ALDH1A1 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.